Statera BioPharma (STAB) Price & Analysis

191 Followers

STAB Stock Chart & Stats

<$0.01

$0.00(0.00%)

At close: Jul 27 4:00 PM EDT

<$0.01

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.00 - $0.03

Previous CloseN/A

Volume25.00

Average Volume (3M)N/A

Market Cap

$14.28K

Enterprise Value$14.42M

Total Cash (Recent Filing)$506.10K

Total Debt (Recent Filing)$7.41M

Price to Earnings (P/E)―

Beta0.83

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.61

Shares Outstanding71,416,040

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-51.50

Price to Sales (P/S)0.00

P/FCF Ratio-2.85

Enterprise Value/Market Cap1.01K

Enterprise Value/Revenue3.91

Enterprise Value/Gross Profit5.57

Enterprise Value/Ebitda-0.73

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

STAB FAQ

What was Statera BioPharma’s price range in the past 12 months?

Statera BioPharma lowest stock price was $0.00 and its highest was $0.03 in the past 12 months.

What is Statera BioPharma’s market cap?

Statera BioPharma’s market cap is $14.28K.

When is Statera BioPharma’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Statera BioPharma’s earnings last quarter?

Statera BioPharma released its earnings results on Nov 14, 2022. The company reported -$0.067 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.067.

Is Statera BioPharma overvalued?

According to Wall Street analysts Statera BioPharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Statera BioPharma pay dividends?

Statera BioPharma does not currently pay dividends.

What is Statera BioPharma’s EPS estimate?

Statera BioPharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Statera BioPharma have?

Statera BioPharma has 71,416,040 shares outstanding.

What happened to Statera BioPharma’s price movement after its last earnings report?

Statera BioPharma reported an EPS of -$0.067 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Statera BioPharma?

Currently, no hedge funds are holding shares in STAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Statera BioPharma

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cutting-edge immunotherapies. These novel treatments aim to address a range of serious conditions, including autoimmune disorders, neutropenia, anemia, emerging viral infections, and various cancers. This development is underpinned by a proprietary technological platform engineered to restore the body's immune system balance and re-establish overall physiological homeostasis. The company's therapeutic strategies are designed to directly stimulate patients' immune systems, specifically eliciting antigen-specific killer T-cells and antibodies to activate crucial defenses against inflammatory, infectious, and cancerous diseases. Statera BioPharma's clinical pipeline features programs such as STAT-201 for Crohn's disease, Entolimod for hematological conditions, STAT-401 for pancreatic cancer, and STAT-205 for COVID-19. The company is also actively exploring therapeutic applications for fibromyalgia and multiple sclerosis. Formerly known as Cytocom, Inc., the company officially adopted the name Statera BioPharma, Inc. in September 2021. Its operations are headquartered in Fort Collins, Colorado.